lapatinib has been researched along with Ductal Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, Y; Aoyama, J; Hatano, T; Hirai, Y; Kijima, N; Nishimura, G; Nojima, Y; Oridate, N; Sano, D; Takada, K; Takahashi, H | 1 |
1 other study(ies) available for lapatinib and Ductal Carcinoma
| Article | Year |
|---|---|
Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma.
Topics: Animals; Carcinoma, Ductal; Humans; Lapatinib; Mice; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Signal Transduction | 2023 |